Skip to content
ASH 2017 logo

ASH 2017

5 interviews51 min

American Society of Hematology Annual Meeting

Interviews and expert commentary from ASH 2017 — study authors and key opinion leaders discuss the findings and their clinical implications.

Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism

Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe

5 February 2018
15 min
Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe

5 February 2018
15 min
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (V

26 January 2018
10 min
Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia

Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia

ATLANTA—Adding anti-BCL-2 therapy with the small-molecule drug venetoclax (VEN) to standard low-dose cytarabine (LDAC) chemotherapy tripled response rates over historical comparators and extended surv

19 January 2018
5 min
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma

Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma

ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple m

15 January 2018
6 min